B
Bullisch
Bullisch · 25%BNR
$4.42
Szenariopreis
$13.250
+0.433 (+3.27%)Zum Schluss
Loading chart…
- Hoch
- 13.400
- Eröffnung
- 12.500
- Volumengewichteter Durchschnittskurs
- 12.99
- Volumen
- 86.68K
- Marktkap.
- 66.17M
- Tief
- 12.320
- Umsatz
- 1.13M
- EV/EBITDA, TTM
- -140.74
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
KI-Analyse of Burning Rock Biotech Limited (BNR)
VerkaufenBurning Rock Biotech Ltd is not a good buy right now due to its significant financial losses and declining revenue. The current price is $10.04, with a 52-week high of $41.72, indicating a substantial drop in value. The company has a negative net income of RMB 18.41 million for Q2 2026 and a year-to-date change of -48.98%, highlighting ongoing financial struggles.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Burning Rock Biotech Limited (BNR) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -3.70.
Alphio-AI-Kursszenarien für BNR
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die BNR halten
Event-Zeitleiste
News
9.509-10NASDAQ.COMBurning Rock Biotech Reports Q2 2026 Financial Results and Updates
5.007-02NewsfilterBurning Rock Founder Increases Company Shareholding
9.506-09seekingalphaBurning Rock Biotech Q1 Financial Results Analysis
- 5.004-02Newsfilter
Burning Rock CEO Yusheng Han Purchases $546K in ADSs, Signaling Confidence
- 9.503-12seekingalpha
Burning Rock Biotech Reports Q4 and Full Year 2025 Financial Results
BNR FAQ – beantwortet von Alphio AI
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).
Burning Rock Biotech Ltd is not a good buy right now due to its significant financial losses and declining revenue. The current price is $10.04, with a 52-week high of $41.72, indicating a substantial drop in value. The company has a negative net income of RMB 18.41 million for Q2 2026 and a year-to-date change of -48.98%, highlighting ongoing financial struggles.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.